Mydecine Innovations Group Inc MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT, ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENTS

 
TIDMMYIG 
 
[image] 
 
MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT, ANNOUNCES CLOSING UNDER 
SHARE SUBSCRIPTION AGREEMENTS 
 
VANCOUVER, BC, 31 October 2023 - Mydecine Innovations Group Inc. ("Mydecine" or 
the "Company") (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology 
company engineering the next wave of innovative medications and treatment 
protocols to directly address mental health with a particular emphasis on 
addiction and PTSD, is pleased to announce that, in connection with: (i) its 
previously announced Common Share Subscription Agreement (the "Opensky 
Subscription Agreement") with OpenSky Opportunities Fund Ltd. ("Opensky") dated 
10 March 2023; and (ii) a Common Share Subscription Agreement dated 25 October 
2023 (the "Standalone Subscription Agreement", and collectively with the Opensky 
Subscription Agreement, the "Subscription Agreements") between the Company and 
an arms-length investor (the "Standalone Investor" and collectively with 
Opensky, the "Investors"), the Company has filed a shelf prospectus supplement 
(the "Prospectus Supplement") to the Company's Final Short Form Base Shelf 
Prospectus for the province of Québec and Amended and Restated Final Short Form 
Base Shelf Prospectus for each of the provinces of Canada, dated 28 January 2022 
(together, the "Shelf Prospectus"). 
 
The Prospectus Supplement provides, among other things, that the Company is 
qualifying the distribution of up to 7,360,000 common shares (each a "Share") in 
the capital of the Company to the Investors under the Subscription Agreements at 
a price of $0.15 per Share for aggregate gross proceeds of up to $1,104,000. 
 
The Company also announces today the closing of Share issuances under the 
Subscription Agreements (the "Offerings"). The Offerings resulted in the 
issuance of 7,360,000 Shares at a price of $0.15 per Share for aggregate gross 
proceeds of $1,104,000. The distribution of such Shares is qualified by the 
Prospectus Supplement. The Company will use the proceeds of the Offering as 
described in the Prospectus Supplement. 
 
An application will be made to the Aquis Stock Exchange ("Aquis") for the 
7,360,000 new Shares to be admitted to trading. Admission is expected to take 
place, and dealings on Aquis in the Shares are expected to commence, at 08:00 on 
or around 3 November 2023. 
 
Following Admission, the Company will have 52,567,458 Ordinary Shares in issue. 
Since the Company currently holds no shares in treasury, the total number of 
voting rights in the Company will therefore be 52,567,458. These figures may 
therefore be used by Shareholders as the denominator for the calculations by 
which they will determine if they are required to notify their interest in, or a 
change in their interest in, the share capital of the Company under the FCA's 
Disclosure Guidance and Transparency Rules. 
 
The Prospectus Supplement and Base Shelf Prospectus are available on the Company 
website and on the Company's profile on the System for Electronic Document 
Analysis and Retrieval (SEDAR+) at www.sedarplus.ca. 
 
About Mydecine Innovations Group 
 
Mydecine Innovations Group is a publicly traded, pre-revenue biopharmaceutical 
company that began operations in North America and Europe in early 2020. 
Mydecine was founded to increase physicians' access to serotonin-modulating 
medicine. Recent research has demonstrated the therapeutic potential of 
psychedelic substances such as psilocybin and MDMA for treating intractable 
conditions such as pain, anxiety, depression, addiction, and PTSD, along with 
neurodegenerative disorders. Mydecine believes these compounds can be safer, 
more effective, and more accessible for patients and medical professionals 
through modern drug chemistry paired with artificial intelligence (AI). Through 
its exclusive partnership with Applied Pharmaceutical Innovation based at the 
University of Alberta, Mydecine is developing innovative medications for target 
indications with high mortality rates that have lacked innovation for decades 
and are controlled by dominant corporations. Mydecine developed several prodrug 
families, beginning with a psilocybin-derived smoking cessation drug undergoing 
a NIDA-funded trial at Johns Hopkins University. Mydecine is also developing 
MYCO-006-short-acting chemical analogs derived from MDMA for treating various 
conditions, including anxiety and pain. Mydecine utilises cutting-edge 
artificial intelligence (AI) and pharma research infrastructure at the 
University of Alberta to develop and manufacture new medications to make them 
affordable and accessible to the general public upon Health Canada and FDA 
approval. The Mydecine team is enthusiastic about its mission and is dedicated 
to creating a positive difference in the lives of others. 
 
The Directors of Mydecine take responsibility for this announcement. 
 
This announcement contains inside information for the purposes of Article 7 of 
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by 
virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in 
accordance with the Company's obligations under Article 17 of MAR. 
 
Learn more at: https://www.mydecine.com/ and follow the company on Twitter, 
LinkedIn, YouTube, and Instagram. 
 
For more information, please contact: 
 
Media Contact 
pr@mydecineinc.com 
 
Investor Relations 
investorrelations@mydecineinc.com 
 
On behalf of the Board of Directors 
 
Joshua Bartch, Chief Executive Officer contact@mydecineinc.com 
 
AQSE Corporate Advisor 
 
Novum Securities LimitedTel: +44 (0)207 399 9400 
 
David Coffman/ George Duxberry 
 
For further information about Mydecine, please visit the Company's profile on 
SEDAR at https://sedar.com/ or visit the Company's website at 
https://www.mydecine.com/. 
 
Forward-Looking Statements 
 
Certain statements in this news release constitute "forward-looking information" 
within the meaning of applicable Canadian securities legislation. Forward 
-looking statements and information are provided for the purpose of providing 
information about management's expectations and plans relating to the future. 
All of the forward-looking information made in this news release is qualified by 
the cautionary statements below and those made in our other filings with the 
securities regulators in Canada. Forward-looking information contained in 
forward-looking statements can be identified by the use of words such as "are 
expected," "is forecast," "is targeted," "approximately," "plans," 
"anticipates," "projects," "anticipates," "continue," "estimate," "believe" or 
variations of such words and phrases or statements that certain actions, events 
or results "may," "could," "would," "might," or "will" be taken, occur or be 
achieved. All statements, other than statements of historical fact, may be 
considered to be or include forward-looking information. This news release 
contains forward-looking information regarding, the use of proceeds and the 
closing of the Offering. Readers are cautioned that these forward-looking 
statements are neither promises nor guarantees, and are subject to risks and 
uncertainties that may cause future results to differ materially from those 
expected. Although the Company has attempted to identify important factors that 
could cause actual results to differ materially from those contained in forward 
-looking information, there may be other factors that cause results not to be as 
anticipated, estimated or intended. There can be no assurance that such 
information will prove to be accurate, as actual results and future events could 
differ materially from those anticipated in such information. 
 
The forward-looking information set forth herein reflects the Company's 
reasonable expectations as at the date of this news release and is subject to 
change after such date. The Company disclaims any intention or obligation to 
update or revise any forward-looking information, whether as a result of new 
information, future events or otherwise, other than as required by law. The 
forward-looking information contained in this news release is expressly 
qualified by this cautionary statement. 
 
This news release shall not constitute an offer to sell or the solicitation of 
an offer to buy nor shall there be any sale of the securities in any State in 
which such offer, solicitation or sale would be unlawful. The securities being 
offered have not been, nor will they be, registered under the United States 
Securities Act of 1933, as amended, and may not be offered or sold in the United 
States absent registration or an applicable exemption from the registration 
requirements of the United States Securities Act of 1933, as amended, and 
applicable state securities laws. 
 
2 
 
MYDECINE INNOVATIONS GROUP INC. 
 
Suite 810-789 West Pender Street, Vancouver, British Columbia, V6C 1H2 T: 604 
-687-2038 
 
 
This information was brought to you by Cision http://news.cision.com 
https://news.cision.com/mydecine-innovations-group-inc/r/mydecine-innovations-group-files-prospectus-supplement--announces-closing-under-share-subscription-a,c3866091 
The following files are available for download: 
https://news.cision.com/mydecine-innovations-group-inc/i/3866091-0-jpeg,c3233950 3866091_0.jpeg 
 
 
END
(END) Dow Jones Newswires
October 31, 2023 03:00 ET (07:00 GMT)
Mydecine Innovations (AQSE:MYIG)
過去株価チャート
から 5 2024 まで 6 2024